The announcement expands Cocrystal's pipeline into high-unmet-need viral indications with no approved treatments, which could attract partnership interest. However, the data is early-stage in vitro only — monitor for in vivo animal data and any collaboration announcements. The $16M market cap makes this a high-risk binary event stock; position sizing should reflect that.
Price Chart
Executive Summary
Cocrystal Pharma announced the discovery of novel pan-viral inhibitors targeting hantavirus, bunyavirus, and influenza, with in vitro potency data showing IC50 <50 nM against hantaan virus. The press release highlights the potential to address significant unmet medical needs, but no financial data, guidance, or clinical trial results were provided.
Key Facts
- Novel pan-viral inhibitors targeting hantavirus, bunyavirus, and influenza announced
- In vitro potency data shows IC50 <50 nM against hantaan virus
- Andes hantavirus outbreak on cruise ship infected up to 11, resulting in 3 deaths
- No approved treatments or vaccines for hantavirus or bunyavirus
- CDI-988, a first pan-viral protease inhibitor, advanced to Phase 1b norovirus challenge study in the US
- No financial data, guidance, or clinical trial results were provided in the filing
Financial Impact
No financial figures provided; pre-revenue clinical-stage biotech with $16M market cap
Risk Factors
- Early-stage preclinical data may not translate to clinical efficacy
- No revenue or near-term catalysts to support valuation
- Dilution risk given $16M market cap and cash burn from multiple programs
- Competition from other antiviral developers targeting similar viruses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025172 |
| Exhibit: ex99-1.htm | 0001493152-26-025172 |
| Document: 0001493152-26-025172-index-headers.html | 0001493152-26-025172 |
| Document: 0001493152-26-025172-index.html | 0001493152-26-025172 |
| Document: 0001493152-26-025172.txt | 0001493152-26-025172 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $1.24 | awaiting T+60 | — | $0.9500 (−23.39%) |
Aug 3, 2026 12w ago | 8-K | $0.9400 | awaiting T+60 | — | $0.9500 (+1.06%) |
Jun 9, 2026 19w ago | 8-K | $1.02 $1.16 | ▲ +13.73% | ▲ +9.91% | $0.9500 (−6.86%) |
Jun 3, 2026 20w ago | 8-K | $1.06 $1.14 | ▲ +7.55% | ▲ +5.05% | $0.9500 (−10.38%) |
May 27, 2026 21w ago | DEFA14A | $1.13 $1.15 | ▲ +1.77% | ▲ +0.03% | $0.9500 (−15.93%) |
May 26, 2026 21w ago | 8-K | $1.13 $1.15 | ▲ +1.33% | ▼ −1.40% | $0.9500 (−15.93%) |
May 15, 2026 23w ago | Press Release | $1.20 $1.08 | ▼ −10.00% | ▼ −14.52% | $0.9500 (−20.83%) |
May 4, 2026 25w ago | EFFECT | $1.31 $0.8703 | ▲ +33.56% | ▲ +35.42% | $0.9500 (+27.48%) |
Apr 2, 2026 29w ago | 8-K | $1.51 $1.05 | ▼ −30.46% | ▼ −44.62% | $0.9500 (−37.09%) |
Mar 31, 2026 29w ago | 8-K | $1.01 $1.02 | ▲ +0.99% | ▼ −11.39% | $0.9500 (−5.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers